Mike is a Senior Advisor on the Frazier Life Sciences team with over 30 years of drug development experience.
Mike joined the Frazier Life Sciences team in 2020 and is a highly experienced drug discoverer and biotech leader. He most recently served as EVP and Head of Genentech’s Research and Early Development (gRED) and was a member of the Roche Corporate Executive Committee in Basel. Mike was responsible for all aspects of gRED innovation, drug discovery and development, and grew a diversity of drug platform types that includes personalized therapeutic vaccines and cellular therapies. Under his leadership, gRED teams also discovered and developed many successful medicines that had meaningful positive impacts for patients. Mike currently serves on the board of directors of Pardes Biosciences, Interline, Atomwise and ERASCA.
Prior to Genentech, Mike was one of the original fifteen employees at Agouron Pharmaceuticals. He built a team that developed protein-structure based design, a novel approach to drug discovery that is utilized globally by drug discovery teams today. His leadership resulted in the discovery of a number of currently marketed anti-cancer agents.
Mike holds a B.S. in Chemistry from the University of California, Los Angeles, and a Ph.D. in synthetic organic chemistry from the California Institute of Technology, and was an American Cancer Society postdoctoral fellow at Columbia University.
University of California, Los Angeles (B.S.)
California Institute of Technology (Ph.D.)